Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood

Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood

Purpose Checkpoint therapy is now the cornerstone of treatment for patients with renal cell carcinoma (RCC) with advanced disease, but biomarkers are lacking to predict which patients will benefit. This study proposes potential immunological biomarkers that could developed for predicting therapeutic...

Full description

Bibliographic Details
Main Authors: Yuan Liu, Haydn Kissick, Viraj A Master, Mehmet A Bilen, Omer Kucuk, Bradley C Carthon, Nataliya Prokhnevska, Ewelina Sobierajska, Rachel Greenwald, Adeboye Osunkoya, Jennifer Wilkinson Carlisle, Caroline S Jansen, Maria Andrea Cardenas, Adriana Moon Reyes, Luke Del Balzo, Patrick Connor Mullane, Deborah Baumgarten, Fares Hosseinzadeh, Scott Wilkinson, Ross Lake, Adam G Sowalsky
Format: Article
Language:English
Published: BMJ Publishing Group 2022-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/7/e004803.full

Internet

https://jitc.bmj.com/content/10/7/e004803.full

Similar Items